Mercados españoles cerrados

Eisai Co., Ltd. (ESALF)

OTC Markets OTCPK - OTC Markets OTCPK Precio demorado. Divisa en USD
Añadir a la lista de favoritos
43,850,00 (0,00%)
Al cierre: 04:00PM EDT

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Sector(es)Healthcare
SectorDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo11.067

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Haruo NaitoCEO, Representative Corporate Officer & DirectorN/AN/A1947
Mr. Gary HendlerSenior VP & President of EMEA RegionN/AN/A1966
Dr. Lynn D. Kramer FAAN, M.D.VP & Chief Clinical OfficerN/AN/A1950
Ms. Yanhui FengSenior Vice PresidentN/AN/A1972
Dr. Nadeem Sarwar Ph.D.PresidentN/AN/AN/A
Mitsuru ShomonVP & CFON/AN/AN/A
Mr. Keisuke NaitoRepresentative Corporate Officer EVP, COO & Chief Growth OfficerN/AN/A1988
Makoto HoketsuVP & Chief Information OfficerN/AN/AN/A
Mr. Masatomi AkanaSenior VP, Chief Government Relations Officer & Chief IR OfficerN/AN/A1967
Shin KatoVP, General Counsel CCO, Corporate officer of Intellectual property Internal ControlN/AN/AN/A
Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Gobierno corporativo

El ISS Governance QualityScore de Eisai Co., Ltd., a día 1 de julio de 2024, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 1; Derechos de los accionistas: 7; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.